Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Rapid Responses to:
|
|
Rapid Responses published:
|
|
|||
|
David JR Hutchon, Consultant Obstetrician Darlington Memorial Hospital. DL3 6HX
Send response to journal:
|
Fisk and Atun point out that “demand for stem cells from cord blood is greater than supply” (1) This is true. The demand is from the baby but the supply is usually artificially manipulated by the cord clamp. This may have very serious consequences for the newborn baby. The solution in this situation is simple. If the baby is allowed to receive as much blood from the placenta as it requires then the supply will always be sufficient. There are mechanisms which naturally partition a volume of blood in the baby and a volume of blood in the placenta. Once the baby has filled its requirements and closed down the placental circulation, there may be sufficient blood left in the placenta to store or to be given for autologous cord blood transplantation.
Common practice If the justification for immediate cord clamping was to increase the volume of blood for cord blood collection this would be totally unethical and probably illegal.
Establishing trust Weeks (7) recently called for a three minute wait before clamping the cord at birth. The question centres around the normal physiological changes which occur in the baby’s circulation and breathing at birth(8), the risks of neonatal anaemia(9), risk of elevated lead levels (10), the potential for mesenchymal stem cells to repair birth injury (11), and the risk of hypovolaemia at birth (12,13). The need for cord blood pH testing is sometimes put forwards as an argument for immediate cord clamping. The result of the test done at birth is rarely timely enough to be of any value to the health of the baby and is simply for medicolegal purposes to try to protect the obstetrician, midwife or hospital. How many parents who know these risks are going to ask for immediate cord clamping? I doubt there would be many but until we provide them with the information we will not know. Patrick O'Brien, spokesman for the Royal College of Obstetricians and Gynecologists said: “The latest research [on cord clamping] does suggest parents should be given a choice and it should be discussed routinely in antenatal classes.” (14)
References Competing interests: None declared |
|||
|
|
|||
|
Stephen McEwan, Chief Executive, Anthony Nolan Trust The Anthony Nolan Trust, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG
Send response to journal:
|
Dear Sirs Fisk and Atun’s balanced critique of the contribution that Virgin Health Bank might make to increased numbers of nationally stored cord blood units is to be welcomed. However, I believe that the role of the Anthony Nolan Trust, an organisation funded by charitable donations, also needs to be taken into account when considering the UK’s future therapeutic use of cord blood and the funding required to increase the country’s cord inventory. Currently, as the major importer from overseas banks of cord material for UK patients, the Charity is playing a key role in stem cell provision. In addition, the Charity is undertaking a pilot cord blood collection scheme in collaboration with King’s College Hospital, London, and has recently set up a purpose-built processing and storage facility in Nottingham. It is planned to increase the number of collection centres over the next few years. Subject to suitable funding, working with centres in ten major hospitals across the UK, the Charity could substantially increase the cord inventory by 20,000 over the next five years. Our experience so far indicates that NHS staff are supportive of the collection of cord blood for our public bank as our collection model includes providing additional charity-funded personnel to work alongside NHS maternity unit staff. The Charity’s Cord Blood Programme has two other important elements: material not suitable for banking will be made available for research initiatives aimed at investigating the possible therapeutic use of the stem cells in cord blood in a wide range of diseases and a system of support is being developed to provide assistance to physicians in selecting the most suitable stem cell graft available for a particular clinical situation. In these ways, the full potential of publically donated cords can hopefully be realised using an alternative funding model not dependent on charging parents which, even with an acceptable collection system, is clearly skewed towards those with the ability to pay. Yours faithfully Dr Steve McEwan Chief Executive Competing interests: Chief Executive The Anthony Nolan Trust |
|||